CN Patent

CN105461720B — 吗啉类酪氨酸激酶抑制剂

Assigned to Nanjing Shenghe Pharmaceutical Research And Development Co Ltd · Expires 2019-08-06 · 7y expired

What this patent protects

本发明属于医药化学领域，涉及一类吗啉类酪氨酸激酶抑制剂，具体涉及一类具有Bruton’s tyrosine kinase(BTK)抑制活性的化合物或其药学可接受的盐、异构体、溶剂合物、结晶或前药，以及含有这些化合物的药物组合物和这些化合物或组合物在药物制备中的应用，本发明提供的化合物表现出优于Ibrutinib的BTK抑制活性。

USPTO Abstract

本发明属于医药化学领域，涉及一类吗啉类酪氨酸激酶抑制剂，具体涉及一类具有Bruton’s tyrosine kinase(BTK)抑制活性的化合物或其药学可接受的盐、异构体、溶剂合物、结晶或前药，以及含有这些化合物的药物组合物和这些化合物或组合物在药物制备中的应用，本发明提供的化合物表现出优于Ibrutinib的BTK抑制活性。

Drugs covered by this patent

Patent Metadata

Patent number
CN105461720B
Jurisdiction
CN
Classification
—
Expires
2019-08-06
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Shenghe Pharmaceutical Research And Development Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.